Diatech Pharmacogenetics

Diatech Pharmacogenetics specializes in the development, manufacturing, and commercialization of molecular diagnostic tools for precision oncology medicine. The company focuses on genomics testing solutions that identify gene mutations and genetic variations targeted by cancer therapies. 

The company’s diagnostic solutions for solid tumor include 1) real-time polymerase chain reaction (PCR), 2) next generation sequencing, 3) pyrosequencing and fragment analysis (of somatic or germline gene variants), and 4) mass spectrometry (instrumentation, kits, and software). Furthermore, it has 80 CE marked in-vitro diagnostics (IVD) for precision medicine. As of July 2023, the company had 450 testing sites across more than 40 countries. The company further claims it has performed over 1 million tests across the globe. 

Key Customers and Partnerships

The company partners with universities, hospitals, and research institutions for the development, production, and commercialization of pharmacogenetics tests including Agena Bioscience, Eurogentec, SensoQuest, and Swift Bioscience. In June 2023, the company partnered with Janssen Pharmaceutica NV to enhance access to precision medicine for bladder cancer patients.

Funding and Financials

In April 2023, the company signed a definitive agreement to obtain a strategic growth investment from global private equity firm TA Associates. As a result, minority investor Alto Partners would completely divest its ownership in the company. This collaboration would provide operational expertise and a global network to support Diatech's expansion into international markets and would further develop market-leading diagnostic solutions in the pharmacogenetics sector.